ABSTRACT Traumatic brain injury (TBI) is a leading cause of morbidity and mortality in young people in industrialized countries. Although various anti-inflammatory and antiapoptotic modalities have shown neuroprotective effects in experimental models of TBI, to date, no specific pharmacological agent aimed at blocking the progression of secondary brain damage has been approved for clinical use. Erythropoietin (Epo) belongs to the cytokine superfamily and has traditionally been viewed as a hematopoiesis-regulating hormone. The newly discovered neuroprotective properties of Epo lead us to investigate its effect in TBI in a mouse model of closed head injury. Recombinant human erythropoietin (rhEpo) was injected at 1 and 24 h after TBI, and the effect on recovery of motor and cognitive functions, tissue inflammation, axonal degeneration, and apoptosis was evaluated up to 14 days. Motor deficits were lower, cognitive function was restored faster, and less apoptotic neurons and caspase-3 expression were found in rhEpo-treated as compared with vehicle-treated animals (P<0.05). Axons at the trauma area in rhEpo-treated mice were relatively well preserved compared with controls (shown by their density; P<0.01). Immunohistochemical analysis revealed a reduced activation of glial cells by staining for GFAP and complement receptor type 3 (CD11b/CD18) in the injured hemisphere of Epo-vs. vehicle-treated animals. We propose that further studies on Epo in TBI should be conducted in order to consider it as a novel therapy for TBI.
raumatic brain injury (TBI) is a leading cause of morbidity and mortality, particularly affecting young people (1) . The pathophysiology of TBI is very complex and still poorly understood. Immediately following the primary impact, activation of several different pathways begins, resulting in secondary brain injury. These include inflammation, oxidative stress, ionic imbalance, increased vascular permeability, mitochondrial dysfunction, and excitotoxic damage (2, 3) . These processes result in brain edema, increased intracranial pressure (ICP), and impaired cerebral perfusion (4) . This combination of cellular and physiologic disturbances causes increased neuronal cell death; enlargement of infarct size; and neurological, motor, and cognitive impairment. Since there are no approved specific pharmacological agents that block the progression of the secondary injury, the current management of TBI is mainly supportive and aims at treating brain edema, reducing ICP, and combating complications such as hypoxia and shock (5) . Despite promising preclinical data, most of the trials that have been performed in recent years have failed to demonstrate any significant improvement in outcome (6) . Recently, two more large clinical trials failed to prove the effects of glucocorticoids (7) and dexanabinol (8) in TBI patients. Various anti-inflammatory and antiapoptotic modalities were found to have neuroprotective effects in experimental models of TBI (9, 10) . These approaches, however, all involve novel molecules requiring years of research before being used in clinical practice.
A novel approach to reduce brain inflammation following different stimuli has been recently proposed based on the newly discovered neuroprotective properties of erythropoietin (Epo) (11) (12) (13) . Thus, Brines et al. administered rhEpo to animals either 24 h before or at various time intervals (up to 6 h) after brain trauma, and the animals were killed 10 days later. rhEpo-treated animals had a reduced volume of injury and a marked decrease in the number of inflammatory cells surrounding the necrotic core of the trauma area (11) . Epo belongs to the cytokine superfamily and has traditionally been viewed as the hematopoiesis-regulating hormone. In its recombinant human form, rhEpo has been widely used for years in clinical settings because it is safe and highly effective for chronic renal-failure patients with Epo-deficient anemia (14) .
Recently, Epo has been shown to act in different tissues both as a growth factor and as an antiapoptotic agent (15) . The Epo receptor (EpoR) is constitutively expressed by a variety of cell types such as neuronal and brain capillary endothelial cells (16) (17) (18) and cardiac myocytes (19, 20) and is up-regulated following hypoxia or ischemia (21) (22) (23) (24) (25) (26) . By binding to its receptor, Epo has an important effect on tissue adaptation to injury (17, 27, 28) . The nonhematopoietic effects of Epo have been most extensively studied in the central nervous system (CNS), where gene expression and Epo protein production were demonstrated in cultured neurons and astrocytes in vitro and by neurons under hypoxic/ischemic conditions or in response to oxidative stress in vivo (22, 23) . Several recent reports have demonstrated that rhEpo can confer neuroprotection and reduce neuronal death in different in vivo and in vitro models of CNS injuries. These include global or focal ischemia/hypoxia, glutamate-mediated excitotoxicity, MPTP (methyl-phenyltetrahydropyridine)-induced Parkinson's (MPTP is a model for Parkinson's disease), and neurotrauma (11, 12, 23, 28, 29) . In addition, rhEpo induces brain endothelial cell proliferation and stimulates neovascularization in vivo (30) . A pioneer study on human stroke patients treated with rhEpo showed a significant improvement of outcome and a strong trend toward reduction of infarct size (31) . Based on these insights, we sought to determine the role of Epo in TBI and to determine its effect on neurobehavioral and cellular levels. In the present study, we used a well-standardized experimental model of closed head injury in mice and rats. We investigated, under a clinically relevant paradigm applying postinjury treatment, the effects of rhEpo on the recovery of motor and cognitive functions and its effects on tissue damage, inflammation, and apoptosis.
MATERIALS AND METHODS

Animals and trauma model
The study was performed according to the guidelines of the Institutional Animal Care Committee of the Hebrew University (Jerusalem, Israel). Male Sabra mice of the Hebrew University strain, 8-to 12-wk old and weighing 35-45 g, and male Sabra rats weighing 180-200 g were used in this study. Animals were bred in a specific pathogen-free environment; kept in cages, with four to six mice per cage, under standard conditions of temperature and light; and fed with food and water ad libitum. Experimental TBI was performed using a weight-drop device previously developed in our laboratory. The models used for mice and rats are similar, yet different energies are applied to the skull, namely, the height and weight of the falling impactor are adjusted according to the species used (10, 32, 33) . Briefly, under ether anesthesia, a midline longitudinal incision was made, skin was retracted, and the skull was exposed. The left anterior frontal area was identified, and a tipped Teflon cone was placed 1 mm lateral to the midline, in the midcoronal plane. The head was fixed and a weight, calibrated according to the age and weight of the animal, was dropped on the cone from a height, resulting in a focal injury to the left hemisphere. After trauma, the animals received supporting oxygenation with 95% O 2 for no longer than 2 min and were returned to their cages.
Erythropoietin treatment protocol
rhEpo was kindly provided by Roche Diagnostics GmbH (Mannheim, Germany). One hour after injury, motor function was assessed using the neurological severity score (NSS, see below), and animals were then stratified into two groups. Each group was treated (i.p.) at 1 and 24 h after injury either with vehicle alone (1.0 ml sterile PBS) or with 5000 U rhEpo (diluted in 1.0 ml sterile PBS) per kilogram of body weight (12) . The effect of rhEpo on hematopoiesis was checked by comparing the hematocrit of rhEpo-treated mice with that of naïve mice.
Evaluation of functional impairment
The NSS, previously developed and validated in our laboratory (34) , is a useful tool for evaluation of posttraumatic functional impairment. It consists of 10 individual tasks reflecting motor function, alertness, and behavior, whereby one point is given for failure to perform a task and zero points for success. A maximal NSS of 10 indicates severe dysfunction, with failure of all tasks, and predicts death within hours, whereas a score of zero is normally achieved by healthy uninjured mice. The NSS at 1 h reflects the initial severity of injury and is inversely correlated with functional outcome. NSS was assessed after injury in vehicle-and rhEpo-treated mice (n=18/group) at 24 h, 72 h and 7, 10, and 14 days by an investigator who was blinded with regard to the study groups. 
Evaluation of cognitive function
The Object Recognition Test (ORT) was developed by Ennaceur and Delacour (35) and is used to evaluate memory function in rodents. Rodents have a natural tendency to explore objects in their vicinity, so that when familiar and new objects are compared, the latter attracts more attention and more time is spent exploring it. The test is based on the differential exploration of familiar vs. new objects and is considered a working-memory test completely free of reference memory component. Testing consists of observations done on two consecutive days. On the first day, 2 or 7 days after injury, mice are placed in the testing cage (a glass aquarium-like transparent box of 60×30 cm) for an hour of habituation. On the following day, they are put back into their original cage into which two identical objects had been placed. During a period of 5 min, the cumulative time spent by the mouse at each of the objects is recorded by an observer blinded to the different groups (baseline). Four hours later, the mice are placed again for 5 min in the same cages; this time, one of the objects is replaced by a different one, and the time spent at each of the objects is recorded (test). The basic measurement is the percent of the time spent by the mouse exploring each object out of the total exploration time. Normal healthy rodents will spend relatively more time exploring a new object as compared with a familiar (i.e., "memorized") one. The vehicle-treated and rhEpo-treated groups (n=17/group) were divided such that 3 or 8 days following injury their cognitive function was evaluated. A group of naïve mice were treated with rhEpo (n=7) to examine the effect of rhEpo on ORT function without injury.
Tissue harvesting, histology, and immunohistochemistry
At the designated times, mice (n=20) and rats (n=15) were anesthetized with a lethal dose of anesthetic and perfused via the ascending aorta with saline followed by cold 4% paraformaldehyde in PBS (pH 7.4). The tissue was postfixed by immersion in the same fixative for 24 h and cryoprotected in 30% sucrose in PBS (pH 7.4) at 4°C. Serial cryostat sections (5-7 μm) were coronally cut anterior to posterior at the area of trauma (frontal lobes), septum, thalamus, and dorsal hippocampus. Sections were stained with hematoxylin/eosin (H&E) for cellular morphology and Bielschowsky silver impregnation stain (36) counterstained with cresyl violet for axons and infiltrating cells identification.
For the study of the effect of rhEpo on the inflammatory response, immunohistochemistry was performed on 6-to 8-μm-thick rat brain cryosections using a biotin/avidin/peroxidase technique (ABC Elite Kit, Vector Laboratories, Burlingame, CA) with diaminobenzidine tetrahydrochloride (DAB) as chromogen (Vector and Jackson, West Grove, PA), as described previously (37) . The primary antibodies were used for detection of complement C3 deposition and for markers of glial cell activation. The analysis of complement activation and deposition by covalent binding in injured tissue was performed with a monoclonal antibody to the rat C3c complement fragment (AntibodyShop, Denmark), since C3 represents the central component of complement activation pathways. The mouse anti-rat C3c antibody was selected because C3c represents the major fragment resulting from C3 cleavage by C3 convertases once the complement cascade is activated. According to the manufacturer's instructions, antisera to C3c have been shown to cross-react with the other C3-derived activation fragments C3b, C3bi, and smaller fragments, all of which carry antigenic determinants of the C3c domain. This antibody does not react with any other proteins of rat serum or plasma, according to the manufacturer. For
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determination of glial cell activation, a polyclonal rabbit anti-rat glial fibrillary acidic protein (GFAP) antibody (Immunon, Detroit, MI) was used as a marker for astrocytes and a monoclonal mouse anti-rat CD11b antibody (Cymbus Biotechnology, UK) specific for the complement receptor type-3 (CR3 or Mac-1; CD11b/CD18) as a marker for microglia and infiltrating myeloid cells. These primary antibodies were used at a titrated optimal dilution of 1:1,000 (C3c) and 1:100 (GFAP and CD11b). The secondary biotinylated antibodies (Vector and Jackson) were used at a dilution of 1:500. For negative control, the appropriate primary antibody was replaced by IgG from nonimmunized mice and rabbits (Vector and Jackson) at the same dilution as the omitted specific antibody.
Quantification of neuronal apoptosis, caspase-3 expression, and axonal damage
Neuronal apoptosis was analyzed at the area of trauma at eight randomly selected pairs of serial sections. In each pair of sections, terminal deoxynucleotidyl transferase-mediated dUTP nick 3′-end labeling (TUNEL) (Apoptosis Detection Kit, R&D Systems, Minneapolis, MN) was performed, and biotinylated nucleotides were detected with a streptavidin-conjugated horseradish peroxidase and diaminobenzidine, according to the manufacturer's instructions. The second section was stained with a rabbit polyclonal antibody raised against activated caspase-3 (R&D Systems). Briefly, sections were incubated overnight with the primary antibody. The following day, sections were reincubated for 2 h in a biotinylated goat anti-rabbit secondary antibody (Novocastra, Newcastle upon Tyne, UK). The tissue was subsequently incubated for 30 min with an avidin-biotin complex (ABC, Novocastra), after which the reaction product was visualized with 0.05% DAB, 0.01% hydrogen peroxide, in PBS (pH 7.4). Sections were then counterstained with hematoxylin, mounted, dehydrated, and placed on cover slips. Control slides were stained only with the primary or the secondary antibody to ensure staining specificity. TUNEL-positive cells were characterized using morphological criteria, and ongoing apoptosis (via the extrinsic pathway) was confirmed by caspase-3 expression. Both normal and apoptotic cells were measured under a light microscope and their quantity was determined in five standardized microscopic fields of 22,500 μm 2 each, defined by an ocular morphometric grid. Animals were divided into two treatment groups: vehicle-and rhEpo-treated. Two observers who were blinded to the identity of tissue sections reviewed the histological preparations independently.
Evaluation of axonal damage was based on the density of axons and the presence of axonal bulbs, spheroids, ovoids, and dilatation or dystrophia (Bielschowsky staining). Axonal pathology was assessed under a light microscope in ∼30 high-power optical fields throughout the corpus callosum and trauma area according to a rating score as follows: 0, normal morphology and density; 1, scattered patches of axonal damage with mild to moderate axonal loss; 2, extensive morphological changes with severe axonal loss.
Histological preparations of all sets of mice were evaluated under light microscopy and photographed on a Zeiss Axioplan 2 imaging microscope. Two independent observers evaluated 30 optical fields for every one of 10 sections per animal (300 optical fields per animal) using a qualitative scale.
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Statistical analysis
Data are expressed as mean ± SE. Statistical analysis was performed on commercially available software (SPSS 9.0 for Windows). The nonparametric Mann-Whitney U test was used for analysis of data that were not normally distributed, such as the neurological scores (NSS). Student's t test was used for the ORT data. Differences between the two groups regarding apoptosis in the trauma area as well as axonal injury were evaluated with Chi-square test. Significance level for all tests was set at P < 0.05. Regarding analysis of histological sections, data are nominal and for this reason we used the Chi-square test for comparison of the two groups.
RESULTS
Effect of posttraumatic rhEpo treatment on the neurobehavioral recovery
The functional recovery after injury was assessed by serial measurements of NSS in the vehicleand rhEpo-treated mice. To ensure a comparable severity of trauma in both groups, mice were assigned to the different groups after their initial NSS was evaluated, at 1 h. As shown in Fig. 1 , both groups had a similar initial NSS 1 h, with a mean of 6.44 ± 0.17 and 6.50 ± 0.25 for the vehicle-and rhEpo-treated groups, respectively, indicating a similar severity of injury. Evaluation of NSS at later time points revealed faster recovery, as shown by lower mean NSS values compared with the control group. Three days after injury, functional recovery of the rhEpo-treated mice was significantly improved, as shown by a lower mean NSS value as compared with control (4.11±0.31 vs. 5.06±0.15, respectively, P<0.05, Mann-Whitney U test). During the 14 day observation period, the difference between the groups became even more significant. Like shown above for mice, rats, treated with rhEpo, also showed a significant recovery of function during 1 wk after trauma (lower NSS; P<0.05, data not shown).
Effect of posttraumatic rhEpo treatment on recovery of cognitive functions
The effect of rhEpo on posttraumatic recovery of memory was examined by applying the ORT. In Fig. 2 , the percent of time spent exploring a new object out of the total exploration time is shown. At day 3 after injury, vehicle-treated mice spent 48.5 ± 4.8% exploring the new object, while rhEpo-treated mice spent 71.7 ± 3.2% of the total exploration time at the new object. This difference is highly significant (P<0.001, Student's t test), indicating that the treated mice are able to distinguish between the "memorized" and new objects. Another group of mice was tested 8 days after injury (Fig. 2) ; however, at this time point the difference between vehicle-and rhEpo-treated groups diminished and became nonsignificant (61.7±2.6 vs. 69.9±4.0, P=0.1; Student's t test), probably due to the spontaneous recovery of the vehicle-treated group.
As expected, the performance of naïve, noninjured, mice treated with rhEpo was identical to that of naïve, nontreated mice, namely, they did recognize the novel object and spent more time exploring it, as compared with the basal exploration time (68.9±6.5 vs. 50.6±2.6, P<0.04).
The effect of rhEpo treatment on neuronal apoptosis and axonal damage
Apoptotic cells were mainly detected at the acute stages (24 h) following injury and were identified with TUNEL (Fig. 3A, 3B ). Activated caspase-3 immunohistochemistry was also (Fig. 3C, 3D ). The percentage of apoptotic neurons was significantly lower in the cortical areas adjacent to trauma in rhEpo-treated animals (Fig. 3B, 3D ) as compared with vehicle-treated animals (Fig. 3A, 3C) . Quantification of the data (see Materials and Methods for details) yielded 7.9 ± 0.4 vs. 27.6 ± 0.6% apoptotic cells, P = 0.033 (Fig. 3E) in the rhEpo-and vehicle-treated mice, respectively. In the hippocampus, neuronal apoptosis was evident in most of the untreated mice at 24 h after trauma, while none of the brain-injured rhEpo-treated animals displayed apoptosis of hippocampal neurons (not shown). When we examined the two groups 24 h following injury, there was no difference between the two regarding the amount of axonal injury or axonal loss. However, at 7 days, a marked effect of rhEpo treatment was evident. Figure 4A -D depicts Bielschowsky silver impregnation staining of Epo-and vehicle-treated brain-injured mice. Axons in the rhEpo-treated mice were relatively well preserved compared with vehicle-treated animals as shown by their density within the area of trauma (P<0.01) (Fig.  4E) . Thus, in rhEpo-treated mice, a significant increase in the percent of normal axonal density (grade 0, P<0.001) and a decrease in the severe axonal loss (grade 2) were found. In contrast, a similar level of moderate axonal loss was found in the brains of both groups (grade 1). Namely, rhEpo treatment shifted the balance of the examined axons toward more normal appearing axonal density.
The effect of rhEpo treatment on posttraumatic neuroinflammation
Rats were sacrificed 7 days after injury for evaluation of the effect of rhEpo on neuroinflammation. Figure 5 Because rhEpo is known to induce erythropoiesis, we checked the hematocrit of naïve mice and compared it to that of the rhEpo-treated mice, 5 days after treatment. As anticipated, rhEpotreated mice displayed elevated levels of hematocrit (54.3±0.7 vs. 44±0.8, P<0.05).
DISCUSSION
The present study demonstrates that rhEpo confers neuroprotection in an in vivo experimental model of TBI and emphasizes its beneficial effect on motor and cognitive functions. The preliminary study was performed in rats and showed improved recovery of neurobehavioral parameters and less inflammation at 7 days after injury (see below). We then extended our studies to the mouse model in order to generalize the phenomenon to other species and to allow, in future studies, the use of specific transgenic and knockout animals, which are only available in mice.
Effect of rhEpo on neurobehavioral and cognitive function
Early administration of rhEpo at 1 and 24 h after trauma improved both functional and cognitive recovery of the mice, similar to the findings in rats. This effect was significant and lasted for >14 days. In addition to improved neurobehavioral recovery, rhEpo-treated mice had significantly less apoptotic nuclei, better preservation of axons, and less inflammatory infiltrates.
The role of Epo as a neuroprotectant has been studied extensively in a wide range of in vitro and in vivo experimental models of brain injury. These studies examined the effects of Epo in models of ischemia (12, 38) , hypoxia (39, 40) , Kainate-induced seizures (11), brain and spinal cord trauma (13, 41) , MPTP-induced Parkinson's disease (42) , and EAE (43), and were recently reviewed in detail (44) (45) (46) .
The findings of Brines et al. (11) showing a reduced volume of injury and a marked decrease in inflammatory cells surrounding the necrotic core of the trauma are in agreement with our present findings in the rat. Adembri et al. studied trauma using an in vitro model of organotypic hippocampal slices and assessed injury by percentage of dead cells (29) . When rhEpo was added to the incubation medium before, immediately after, and up to 30 min postinjury, the neuroprotective effect was evident as early as 24 h later and became significant at 48 h postinjury.
Similarly to the brain, the spinal cord also expresses Epo and EpoR and favorably responds to Epo treatment (41, 47) . Gorio et al. (13) reported that rhEpo administration in rat models of spinal cord compression and contusion was associated with markedly improved neurological recovery as early as 12 h in the compression model and at 4 days at the weight drop model (13) . These rhEpo-treated rats had marked preservation of the white matter, minimal axonal degeneration, no apoptosis, and reduced inflammatory infiltrate compared with vehicle-treated animals. Similar findings regarding neuroprotective effects of rhEpo in spinal cord injury were reported by Celik et al. (41) . All the above reports are in remarkable agreement with our current findings in closed head injury model of rat and mouse.
The effect of rhEpo on the recovery of cognitive functions after head trauma has not been studied to date, to our knowledge. Our present findings on the improved performance in the ORT are supported by several studies using other experimental models of brain injury. Kumral et al. (48) showed that rat pups treated with rhEpo had a significantly better performance in the Morris water maze (MWM) test compared with nontreated pups in a neonatal rat model of hypoxiaischemia. Mogensen et al. (49) subjected rats to bilateral transections of the fimbria-fornix and rhEpo treatment and showed that their performance in the MWM significantly improved the posttraumatic functional recovery of the place learning task. Catania et al. (50) studied the effect of Epo in a gerbil transient brain ischemia model and reported that rhEpo prevented cognition impairment in the passive avoidance test. These results demonstrate that the neuroprotective effects of rhEpo in brain ischemia are associated with the preservation of learning function. Few studies examined the effect of rhEpo treatment on cognitive function in chronic dialysis patients and a clear improvement was shown. Yet, these studies did not differentiate between the hematopoietic effect of rhEpo and its nonhematopoietic neuroprotective effect (51) (52) (53) . Our current findings showing the beneficial effect of rhEpo in the ORT are in agreement with these reports and point to a possible role of Epo in memory function. Taken together, these reports fully agree with our current findings and suggest a role for Epo in recovery of cognitive functions.
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Effect of rhEpo on histopathology
To better understand the mechanism by which Epo provides neuroprotection, we studied the effects of rhEpo treatment on histopathology, inflammation, and apoptosis in different areas of the brain at two defined time points (acute, t=24 h; chronic, t=7 days after injury).
Inflammation and apoptosis
Accumulation of inflammatory cells into the impact site and surrounding area is well documented following trauma. This phenomenon is a cornerstone of inflammation and has been described extensively, including in our model (54) (55) (56) (57) . Inflammation was assessed in rats 7 days after injury and is expressed by increased intracerebral complement deposition and activation of glial cells (expressed as GFAP-and CR3-positive cells). These were markedly attenuated in the rhEpo-treated as compared with vehicle-treated animals.
Neuronal apoptosis was assessed by TUNEL staining and morphological criteria and was confirmed with activated caspase-3 immunohistochemistry. It was mainly evident at the acute (24 h) period, and that time point was chosen to examine the effect of rhEpo. A clear decrease of apoptosis was found in cortical neurons in the rhEpo-treated animals. This finding was expected and has been described in numerous studies (44) (45) (46) 58) . Apoptosis has been described as an inflammation-limiting mechanism that is activated when the extent of the inflammatory response in and around the trauma area has to be contained.
Several mechanisms have been proposed to explain the antiapoptotic effect of Epo both in hematopoiesis and neurons. Silva et al. (59) studied a human erythroid progenitor cell line and showed that apoptosis was repressed by Epo via up-regulation of the Bcl-X L gene, an antiapoptotic gene of the Bcl-2 family. This concept is supported by the finding that Bcl-X L knockout mice exhibit severe anemia during embryogenesis (60) . Activation of EpoR prevents apoptosis by triggering crosstalk between signaling pathways of JAK-2 and NF-κB (61) . The final net effect of these processes is production of antiapoptotic proteins of the Bcl-X L family and preservation of DNA integrity (44, 62) .
The effect of rhEpo on axonal injury
The effect of rhEpo on axonal injury was studied in different areas of the brain at the acute (24 h) and chronic (7 days) time point after injury. We found that in the acute phase there was no difference in axonal injury or axonal loss between the rhEpo and the control groups. However, at 7 days postinjury, axons of the treated group were relatively well preserved as shown by their density within the area of trauma (P<0.01) (Fig. 4) . This finding may indicate that axonal injury induced at the acute stages following trauma is at least partly reversible by Epo treatment. Alternatively, one can propose that rhEpo treatment reduces ongoing axonal damage at the chronic stages.
It may therefore be suggested that in addition to protecting neurons, Epo protects axons following TBI. Axons may degenerate either due to the correspondent neuronal body degeneration and/or due to a direct impact of the mechanical insult on the axon itself. From the Page 9 of 20 (page number not for citation purposes) present findings it may not be concluded whether the protective effect of Epo on axons is an epiphenomenon to the protection of neurons or a direct effect on axons.
In conclusion, our present findings add to the cumulating evidence on the nonhematopoietic neuroprotective effects of Epo. Note that although rhEpo treatment led to an increase in the hematocrit, this should not be a concern regarding its application in human TBI, since it should be given no more than twice after injury, and not on a chronic basis. In view of its long-term safe use in patients with end-stage renal failure, and in view of the lack of pharmacological therapy to head trauma patients and the success of Epo-treatment in clinical stroke, we believe that a clinical trial using Epo after TBI is warranted. 2 . rhEpo improves cognitive function after closed head injury. Mice were treated with rhEpo as described in Fig.   1 , and memory function was tested using the ORT on day 3 or day 8 after injury. The absolute time spent exploring each of the two objects was recorded and the percent exploration time at each object was calculated, first, with identical objects (baseline) and then, 4 h later (test), with one of the objects replaced by a new one. At day 3, rhEpo-treated mice spent a significantly longer time at exploring the new object (**P<0.001), indicating their ability to distinguish between the familiar and new objects. The improvement in rhEpo-treated mice is lost at day 8 as the nontreated mice partly regain this "memory" function, and there is no significant difference (ns) between the two groups. 
